Dendreon beats Street

Dendreon Corp. (NASDAQNDN) reported 4Q12 net revenues of prostate cancer drug Provenge sipuleucel-T of $85.5 million, beating the Street's estimate of $82.9 million and up 11% from $77 million in 4Q11. Provenge -- Dendreon's sole marketed product -- recorded 2012 net revenues of $325.3 million, up 52% from $213.5 million in 2011 and just edging out the Street's estimate of $324.6 million. The company reported a 4Q12 GAAP loss per share of $0.26 and a full year loss per share of $2.65. The Street was expecting a loss per share for the quarter of $0.56 and a 2012 loss per share of $2.81. ...